SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: alan laValley who wrote (8781)5/31/1998 10:49:00 PM
From: VLAD  Read Replies (1) of 23519
 
al,

I would like to respond to a few of your points:

2)"those that short stocks are no fools playing a very dangerous game" Don't be so sure. I feel that the significant increase in shares shorted was not institutional. Why? I believe that many of the little fish have added to the short position assuming that the prior 10 million shorts knew something we don't when in fact most of the shares shorted are hedged against long positions--so the institutions don't really care about fundamentals on this stock but only on price direction. Personally, in the last 6 months I have lost over $75,000.00 shorting stocks with high short interest that ran up for no fundamental reasons.

3)"my emotions may have clouded my judgement" Yes, greed drove the price above 40 and now fear puts us below 10.

5)A 2Q loss is already estimated at -.15. Lawsuit expenses are covered by insurance. If you want a few case histories of lawsuits where the company was guilty as sin and settled I will be happy to provide them--insurance always covered the costs involved.

6)When you are in bed with the FDA you get your way. Kind of like why everyone hates the bosses girlfriend when she works for him. She can do no wrong since she provides the boss with "extra" favors. Don't get mixed up as to who the boss is between Pfizer and the FDA (hint: its not the FDA). Did you notice last week how Pfizer was the one that responded to the situation regarding the 6 deaths yet nothing was announced by the FDA? Just goes to show you who is really running the show.

7)This very point you make supports the point I make in your second point. Even the company itself thought that an average price of $14.50 per share was a good deal on the open market. Wouldn't you agree that the company itself knows more about the inside workings than the shorts?

How many vivus longs are disappointed at Fridays close price? I would say all of them unless they paid less than $9.00/share.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News